Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of UCB's Bepranemab?
Bepranemab is a monoclonal antibody commercialized by UCB, with a leading Phase II program in Alzheimer's Disease;Mild Cognitive Impairment. According...